|
1
|
Lian Y, Wang A, Wei L, Yao J, Bulloch G, Wu Z, Zhao Y. Mitochondrial DNA mutations in HIV-exposed uninfected infants following the cessation of triple antiretroviral drugs. J Antimicrob Chemother 2024; 79:307-311. [PMID: 38069910 DOI: 10.1093/jac/dkad378] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Accepted: 11/26/2023] [Indexed: 02/02/2024] Open
Abstract
OBJECTIVES Mitochondrial mutations in HIV-exposed uninfected (HEU) infants after cessation of ART are rarely studied. We analysed a group of HEU newborns born to mothers with late HIV diagnosis who received three doses of ART immediately after birth. We observed mitochondrial DNA (mtDNA) mutations at different times of withdrawal. METHODS The study was based on a clinical trial conducted from 2015 to 2020. Newborns of the intervention group who met the criteria for this study received triple antiretroviral drugs, zidovudine + lamivudine + nevirapine, within 2 h after the birth, as post-partum prophylaxis, and at 14 days were switched to zidovudine + lamivudine + lopinavir/ritonavir, which was continued until 6 weeks of age. From August to November 2019, blood samples from HEU infants were also collected after ceasing 12 months of ART, and analysed for mtDNA. RESULTS Our study found that mtDNA mutations remained prevalent in HEU infants a few years after three ARTs were stopped immediately after birth. Among them, D-loop, ND1 and CYTB are the first three mutated regions during different withdrawal periods. This pattern of mutations is similar to, but not exactly consistent with, HIV-infected children receiving standard ART. CONCLUSIONS Further studies are needed to determine the effects of these mutations on the development of HEU infants and whether stopping ART leads to the restoration of mitochondrial function.
Collapse
Affiliation(s)
- Yuting Lian
- National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ailing Wang
- National Center for Women and Children's Health, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lai Wei
- National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Jun Yao
- National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Gabriella Bulloch
- Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia
| | - Zunyou Wu
- National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yan Zhao
- National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
|
2
|
Desquiret-Dumas V, D’Ottavi M, Monnin A, Goudenège D, Méda N, Vizeneux A, Kankasa C, Tylleskar T, Bris C, Procaccio V, Nagot N, Van de Perre P, Reynier P, Molès JP. Long-Term Persistence of Mitochondrial DNA Instability in HIV-Exposed Uninfected Children during and after Exposure to Antiretroviral Drugs and HIV. Biomedicines 2022; 10:biomedicines10081786. [PMID: 35892686 PMCID: PMC9331317 DOI: 10.3390/biomedicines10081786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2022] [Revised: 07/18/2022] [Accepted: 07/20/2022] [Indexed: 11/16/2022] Open
Abstract
HIV-exposed uninfected (HEU) children show impaired health outcomes during childhood. A high rate of mitochondrial DNA (mtDNA) instability was reported in the blood of HEU at birth. We aimed to explore the relationship between these health outcomes and mtDNA deletions over time in a case series of 24 HEU children. MtDNA instability was assessed by deep sequencing and analyzed by eKLIPse-v2 algorithm at three time points, namely birth, 1 year, and 6 years of age. Association between mtDNA deletion and health outcomes, including growth, clinical, and neurodevelopmental parameters, were explored using univariate statistical analyses and after stratification with relevant variables. HEU children were selected with an equal male:female ratio. An elevated number of mtDNA deletions and duplications events was observed at 7 days’ post-partum. Median heteroplasmy increased at one year of life and then returned to baseline by six years of age. The mtDNA instability was acquired and was not transmitted by the mother. No risk factors were significantly associated with mtDNA instability. In this small case series, we did not detect any association between any health outcome at 6 years and mtDNA instability measures. A significant effect modification of the association between the duration of maternal prophylaxis and child growth was observed after stratification with heteroplasmy rate. Genomic instability persists over time among HEU children but, despite its extension, stays subclinical at six years.
Collapse
Affiliation(s)
- Valérie Desquiret-Dumas
- Department of Biochemistry and Genetics, University Hospital of Angers, F-49000 Angers, France; (V.D.-D.); (D.G.); (C.B.); (V.P.); (P.R.)
- UMR MITOVASC, CNRS 6015, INSERM U1083, University of Angers, F-49000 Angers, France
| | - Morgana D’Ottavi
- Pathogenesis and Control of Chronic and Emerging Infections, INSERM, Etablissement Français du Sang, University of Montpellier, University of Antilles, F-34394 Montpellier, France; (M.D.); (A.M.); (A.V.); (N.N.); (P.V.d.P.)
| | - Audrey Monnin
- Pathogenesis and Control of Chronic and Emerging Infections, INSERM, Etablissement Français du Sang, University of Montpellier, University of Antilles, F-34394 Montpellier, France; (M.D.); (A.M.); (A.V.); (N.N.); (P.V.d.P.)
| | - David Goudenège
- Department of Biochemistry and Genetics, University Hospital of Angers, F-49000 Angers, France; (V.D.-D.); (D.G.); (C.B.); (V.P.); (P.R.)
- UMR MITOVASC, CNRS 6015, INSERM U1083, University of Angers, F-49000 Angers, France
| | - Nicolas Méda
- Centre MURAZ, Bobo-Dioulasso 01 B.P. 390, Burkina Faso;
| | - Amélie Vizeneux
- Pathogenesis and Control of Chronic and Emerging Infections, INSERM, Etablissement Français du Sang, University of Montpellier, University of Antilles, F-34394 Montpellier, France; (M.D.); (A.M.); (A.V.); (N.N.); (P.V.d.P.)
| | - Chipepo Kankasa
- Department of Paediatrics and Child Health, University Teaching Hospital, Lusaka P.O. Box 50001, Zambia;
| | - Thorkild Tylleskar
- Centre for International Health, University of Bergen, N-5020 Bergen, Norway;
| | - Céline Bris
- Department of Biochemistry and Genetics, University Hospital of Angers, F-49000 Angers, France; (V.D.-D.); (D.G.); (C.B.); (V.P.); (P.R.)
- UMR MITOVASC, CNRS 6015, INSERM U1083, University of Angers, F-49000 Angers, France
| | - Vincent Procaccio
- Department of Biochemistry and Genetics, University Hospital of Angers, F-49000 Angers, France; (V.D.-D.); (D.G.); (C.B.); (V.P.); (P.R.)
- UMR MITOVASC, CNRS 6015, INSERM U1083, University of Angers, F-49000 Angers, France
| | - Nicolas Nagot
- Pathogenesis and Control of Chronic and Emerging Infections, INSERM, Etablissement Français du Sang, University of Montpellier, University of Antilles, F-34394 Montpellier, France; (M.D.); (A.M.); (A.V.); (N.N.); (P.V.d.P.)
| | - Philippe Van de Perre
- Pathogenesis and Control of Chronic and Emerging Infections, INSERM, Etablissement Français du Sang, University of Montpellier, University of Antilles, F-34394 Montpellier, France; (M.D.); (A.M.); (A.V.); (N.N.); (P.V.d.P.)
| | - Pascal Reynier
- Department of Biochemistry and Genetics, University Hospital of Angers, F-49000 Angers, France; (V.D.-D.); (D.G.); (C.B.); (V.P.); (P.R.)
- UMR MITOVASC, CNRS 6015, INSERM U1083, University of Angers, F-49000 Angers, France
| | - Jean-Pierre Molès
- Pathogenesis and Control of Chronic and Emerging Infections, INSERM, Etablissement Français du Sang, University of Montpellier, University of Antilles, F-34394 Montpellier, France; (M.D.); (A.M.); (A.V.); (N.N.); (P.V.d.P.)
- Correspondence: ; Tel.: +33-434-35-91-07
| |
Collapse
|
|
3
|
Durand M, Nagot N, Nhu QBT, Vallo R, Thuy LLT, Duong HT, Thanh BN, Rapoud D, Quillet C, Tran HT, Michel L, Tuyet TNT, Hai OKT, Hai VV, Feelemyer J, Perre PV, Jarlais DD, Minh KP, Laureillard D, Molès JP. Mitochondrial Genotoxicity of Hepatitis C Treatment among People Who Inject Drugs. J Clin Med 2021; 10:jcm10214824. [PMID: 34768343 PMCID: PMC8584601 DOI: 10.3390/jcm10214824] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Revised: 10/15/2021] [Accepted: 10/18/2021] [Indexed: 12/12/2022] Open
Abstract
Antiviral nucleoside analogues (ANA) are newly used therapeutics acting against the hepatitis C virus (HCV). This class of drug is well known to exhibit toxicity on mitochondrial DNA (mtDNA). People who inject drugs (PWID) are particularly affected by HCV infection and cumulated mitotoxic drug exposure from HIV treatments (antiretrovirals, ARV) and other illicit drugs. This study aims to explore the impact of direct-acting antiviral (DAA) treatments on mtDNA among PWID. A total of 470 actively injecting heroin users were included. We used quantitative PCR on whole blood to determine the mitochondrial copy number per cell (MCN) and the proportion of mitochondrial DNA deletion (MDD). These parameters were assessed before and after DAA treatment. MDD was significantly increased after HCV treatment, while MCN did not differ. MDD was even greater when subjects were cotreated with ARV. In multivariate analysis, we identified that poly-exposure to DAA and daily heroin injection or regular consumption of methamphetamines were positively associated with high MCN loss while DAA and ARV treatments or methadone use were identified as risk factors for having mtDNA deletion. These observations deserve attention since they were previously associated with premature cell ageing or cell transformation and therefore call for a long-term follow-up.
Collapse
Affiliation(s)
- Mélusine Durand
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, INSERM, EFS, University of Antilles, 34394 Montpellier, France; (N.N.); (R.V.); (D.R.); (C.Q.); (P.V.P.); (D.L.); (J.-P.M.)
- Correspondence: ; Tel.: +33-43435-9120
| | - Nicolas Nagot
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, INSERM, EFS, University of Antilles, 34394 Montpellier, France; (N.N.); (R.V.); (D.R.); (C.Q.); (P.V.P.); (D.L.); (J.-P.M.)
| | - Quynh Bach Thi Nhu
- Faculty of Public Health, Hai Phong University of Medicine and Pharmacy, Haiphong 04212, Vietnam; (Q.B.T.N.); (L.L.T.T.); (H.T.D.); (B.N.T.); (H.T.T.); (K.P.M.)
| | - Roselyne Vallo
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, INSERM, EFS, University of Antilles, 34394 Montpellier, France; (N.N.); (R.V.); (D.R.); (C.Q.); (P.V.P.); (D.L.); (J.-P.M.)
| | - Linh Le Thi Thuy
- Faculty of Public Health, Hai Phong University of Medicine and Pharmacy, Haiphong 04212, Vietnam; (Q.B.T.N.); (L.L.T.T.); (H.T.D.); (B.N.T.); (H.T.T.); (K.P.M.)
| | - Huong Thi Duong
- Faculty of Public Health, Hai Phong University of Medicine and Pharmacy, Haiphong 04212, Vietnam; (Q.B.T.N.); (L.L.T.T.); (H.T.D.); (B.N.T.); (H.T.T.); (K.P.M.)
| | - Binh Nguyen Thanh
- Faculty of Public Health, Hai Phong University of Medicine and Pharmacy, Haiphong 04212, Vietnam; (Q.B.T.N.); (L.L.T.T.); (H.T.D.); (B.N.T.); (H.T.T.); (K.P.M.)
| | - Delphine Rapoud
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, INSERM, EFS, University of Antilles, 34394 Montpellier, France; (N.N.); (R.V.); (D.R.); (C.Q.); (P.V.P.); (D.L.); (J.-P.M.)
| | - Catherine Quillet
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, INSERM, EFS, University of Antilles, 34394 Montpellier, France; (N.N.); (R.V.); (D.R.); (C.Q.); (P.V.P.); (D.L.); (J.-P.M.)
| | - Hong Thi Tran
- Faculty of Public Health, Hai Phong University of Medicine and Pharmacy, Haiphong 04212, Vietnam; (Q.B.T.N.); (L.L.T.T.); (H.T.D.); (B.N.T.); (H.T.T.); (K.P.M.)
| | - Laurent Michel
- CESP UMR1018, Paris Saclay, Pierre Nicole Center, French Red Cross, 75005 Paris, France;
| | - Thanh Nham Thi Tuyet
- Supporting Community Development Initiatives, Hanoi 11513, Vietnam; (T.N.T.T.); (O.K.T.H.)
| | - Oanh Khuat Thi Hai
- Supporting Community Development Initiatives, Hanoi 11513, Vietnam; (T.N.T.T.); (O.K.T.H.)
| | - Vinh Vu Hai
- Infectious & Tropical Diseases Department, Viet Tiep Hospital, Haiphong 04708, Vietnam;
| | - Jonathan Feelemyer
- School of Global Public Health, New York University, New York, NY 10003, USA; (J.F.); (D.D.J.)
| | - Philippe Vande Perre
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, INSERM, EFS, University of Antilles, 34394 Montpellier, France; (N.N.); (R.V.); (D.R.); (C.Q.); (P.V.P.); (D.L.); (J.-P.M.)
| | - Don Des Jarlais
- School of Global Public Health, New York University, New York, NY 10003, USA; (J.F.); (D.D.J.)
| | - Khue Pham Minh
- Faculty of Public Health, Hai Phong University of Medicine and Pharmacy, Haiphong 04212, Vietnam; (Q.B.T.N.); (L.L.T.T.); (H.T.D.); (B.N.T.); (H.T.T.); (K.P.M.)
| | - Didier Laureillard
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, INSERM, EFS, University of Antilles, 34394 Montpellier, France; (N.N.); (R.V.); (D.R.); (C.Q.); (P.V.P.); (D.L.); (J.-P.M.)
- Infectious & Tropical Diseases Department, Caremeau University Hospital, 30029 Nîmes, France
| | - Jean-Pierre Molès
- Pathogenesis and Control of Chronic and Emerging Infections, University of Montpellier, INSERM, EFS, University of Antilles, 34394 Montpellier, France; (N.N.); (R.V.); (D.R.); (C.Q.); (P.V.P.); (D.L.); (J.-P.M.)
| |
Collapse
|
|
4
|
Monnin A, Vizeneux A, Nagot N, Eymard-Duvernay S, Meda N, Singata-Madliki M, Ndeezi G, Tumwine JK, Kankasa C, Goga A, Tylleskär T, Van de Perre P, Molès JP. Longitudinal Follow-Up of Blood Telomere Length in HIV-Exposed Uninfected Children Having Received One Year of Lopinavir/Ritonavir or Lamivudine as Prophylaxis. CHILDREN (BASEL, SWITZERLAND) 2021; 8:796. [PMID: 34572228 PMCID: PMC8468502 DOI: 10.3390/children8090796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Revised: 08/27/2021] [Accepted: 08/30/2021] [Indexed: 11/16/2022]
Abstract
Telomere shortening can be enhanced upon human immunodeficiency virus (HIV) infection and by antiretroviral (ARV) exposures. The aim of this study was to evaluate the acute and long-term effect on telomere shortening of two ARV prophylaxes, lopinavir/ritonavir (LPV/r) and lamivudine (3TC), administered to children who are HIV-exposed uninfected (CHEU) to prevent HIV acquisition through breastfeeding during the first year of life, and to investigate the relationship between telomere shortening and health outcomes at six years of age. We included 198 CHEU and measured telomere length at seven days of life, at week-50 and at six years (year-6) using quantitative polymerase chain reaction. At week-50, telomere shortening was observed among 44.3% of CHEU, irrespective of the prophylactic treatment. Furthermore, this telomere shortening was neither associated with poor growth indicators nor neuropsychological outcomes at year-6, except for motor abilities (MABC test n = 127, β = -3.61, 95%CI: -7.08, -0.14; p = 0.04). Safety data on telomere shortening for infant HIV prophylaxis are scarce. Its association with reduced motor abilities deserves further attention among CHEU but also HIV-infected children receiving ARV treatment.
Collapse
Affiliation(s)
- Audrey Monnin
- Pathogenèse et Contrôle des Infections Chroniques, INSERM U1058, Université Montpellier, Etablissement Français du Sang, University of Antilles, 34093 Montpellier, France; (A.M.); (A.V.); (N.N.); (S.E.-D.); (P.V.d.P.)
| | - Amélie Vizeneux
- Pathogenèse et Contrôle des Infections Chroniques, INSERM U1058, Université Montpellier, Etablissement Français du Sang, University of Antilles, 34093 Montpellier, France; (A.M.); (A.V.); (N.N.); (S.E.-D.); (P.V.d.P.)
| | - Nicolas Nagot
- Pathogenèse et Contrôle des Infections Chroniques, INSERM U1058, Université Montpellier, Etablissement Français du Sang, University of Antilles, 34093 Montpellier, France; (A.M.); (A.V.); (N.N.); (S.E.-D.); (P.V.d.P.)
| | - Sabrina Eymard-Duvernay
- Pathogenèse et Contrôle des Infections Chroniques, INSERM U1058, Université Montpellier, Etablissement Français du Sang, University of Antilles, 34093 Montpellier, France; (A.M.); (A.V.); (N.N.); (S.E.-D.); (P.V.d.P.)
| | - Nicolas Meda
- Centre Muraz, Bobo-Dioulasso 01 P.O. Box 390, Burkina Faso;
| | - Mandisa Singata-Madliki
- Effective Care Research Unit, Cecilia Makiwane Hospital, University of Fort Hare, East London 5207, South Africa;
| | - Grace Ndeezi
- Department of Paediatrics and Child Health, School of Medicine, College of Health Sciences, Makerere University, Kampala P.O. Box 317, Uganda; (G.N.); (J.K.T.)
| | - James Kashugyera Tumwine
- Department of Paediatrics and Child Health, School of Medicine, College of Health Sciences, Makerere University, Kampala P.O. Box 317, Uganda; (G.N.); (J.K.T.)
- School of Medicine, Kabale University, Kabale P.O. Box 317, Uganda
| | - Chipepo Kankasa
- Department of Paediatric and Child Health, University Teaching Hospital, University of Zambia School of Medicine, Lusaka P.O. Box 50110, Zambia;
| | - Ameena Goga
- HIV Prevention Research Unit, South African Medical Research Council, Private Bag x385, Pretoria 0001, South Africa;
| | - Thorkild Tylleskär
- Centre for International Health, Faculty of Medicine, University of Bergen, 5009 Bergen, Norway;
| | - Philippe Van de Perre
- Pathogenèse et Contrôle des Infections Chroniques, INSERM U1058, Université Montpellier, Etablissement Français du Sang, University of Antilles, 34093 Montpellier, France; (A.M.); (A.V.); (N.N.); (S.E.-D.); (P.V.d.P.)
| | - Jean-Pierre Molès
- Pathogenèse et Contrôle des Infections Chroniques, INSERM U1058, Université Montpellier, Etablissement Français du Sang, University of Antilles, 34093 Montpellier, France; (A.M.); (A.V.); (N.N.); (S.E.-D.); (P.V.d.P.)
| |
Collapse
|